Craddock, Charles F <br/><br/>
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Nov 2017 
 - 6430-6440 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-17-1423  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Azacitidine--administration & dosage<br/>Combined Modality Therapy<br/>Cyclin-Dependent Kinase Inhibitor p16<br/>Cyclin-Dependent Kinase Inhibitor p18--genetics<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Female<br/>Histone Deacetylase Inhibitors--administration & dosage<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Isocitrate Dehydrogenase--genetics<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Treatment Outcome<br/>Tumor Suppressor Protein p53--genetics<br/>Vorinostat